Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatm
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
10:15am, Tuesday, 25'th Feb 2025
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
07:00am, Tuesday, 25'th Feb 2025
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
08:00am, Sunday, 19'th Jan 2025
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical du
Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 15'th Jan 2025
Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
07:00am, Friday, 10'th Jan 2025
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
07:36pm, Monday, 16'th Dec 2024
Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
New Strong Buy Stocks for November 15th
05:45am, Friday, 15'th Nov 2024
FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024.
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
06:36pm, Thursday, 14'th Nov 2024
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago.
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
04:05pm, Thursday, 14'th Nov 2024
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (G
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
04:30pm, Wednesday, 02'nd Oct 2024
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Phase 1 study showed significant
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
10:47am, Friday, 09'th Aug 2024
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Of
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
06:35pm, Monday, 05'th Aug 2024
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago.
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
04:01pm, Monday, 05'th Aug 2024
CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatm
